Current Evidence on the Benefit of Exercise in Cancer Patients: Effects on Cardiovascular Mortality, Cardiotoxicity, and Quality of Life
- PMID: 39077533
- PMCID: PMC11264125
- DOI: 10.31083/j.rcm2406160
Current Evidence on the Benefit of Exercise in Cancer Patients: Effects on Cardiovascular Mortality, Cardiotoxicity, and Quality of Life
Abstract
Cancer and its treatments affect cardiovascular (CV) health, including an increased risk of CV death, decreased cardiorespiratory fitness (CRF), and cardiac dysfunction. Moreover, cancer-related fatigue and worse quality of life (QoL) are highly prevalent adverse effects experienced by patients during treatment and can persist years after therapy ends. Physical exercise has been proposed as a strategy to improve different aspects of life of cancer patients, and is recommended as a therapy in cardio-oncology guidelines. Exercise interventions reduce fatigue and improve QoL in patients with both solid tumors and hematological malignancies, although there is a lack of awareness of exercise recommendations, timing, and referral to such programs. New evidence indicates that physical activities improve CRF, which can lead to a reduction in CV mortality. Furthermore, cardiac dysfunction is a side effect of many oncological treatments, which may be mitigated by exercise interventions according to preclinical studies and recent publications. Nevertheless, specific physical exercise programs are not widely used in cancer patients. Thus, the goal of this review was to describe the current evidence on the benefits of exercise in cancer patients, the gaps that remain, and an approach to exercise prescription.
Keywords: cardio-oncology; cardiorespiratory fitness; cardiotoxicity; cardiovascular health.
Copyright: © 2023 The Author(s). Published by IMR Press.
Conflict of interest statement
The author declares no conflict of interest. Sergio Moral is serving as Guest Editor of this journal. We declare that Sergio Moral had no involvement in the peer review of this article and has no access to information regarding its peer review. Full responsibility for the editorial process for this article was delegated to Peter Kokkinos.
Figures


References
-
- Nonaka M, Hosoda H, Uezono Y. Cancer treatment-related cardiovascular disease: Current status and future research priorities. Biochemical Pharmacology . 2021;190:114599. - PubMed
-
- Kobo O, Khattak S, Lopez-Mattei J, Van Spall HGC, Graham M, Cheng RK, et al. Trends in cardiovascular mortality of cancer patients in the US over two decades 1999-2019. International Journal of Clinical Practice . 2021;75:e14841. - PubMed
-
- Haykowsky MJ, Beaudry R, Brothers RM, Nelson MD, Sarma S, La Gerche A. Pathophysiology of exercise intolerance in breast cancer survivors with preserved left ventricular ejection fraction. Clinical Science . 2016;130:2239–2244. - PubMed
-
- Cramer L, Hildebrandt B, Kung T, Wichmann K, Springer J, Doehner W, et al. Cardiovascular function and predictors of exercise capacity in patients with colorectal cancer. Journal of the American College of Cardiology . 2014;64:1310–1319. - PubMed
-
- Zamorano JL, Lancellotti P, Muñoz DR, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Kardiologia Polska . 2016;74:1193–1233. (In Polish) - PubMed
Publication types
LinkOut - more resources
Full Text Sources